Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Salivary Thiocyanate as a Biomarker of Cystic Fibrosis Transmembrane Regulator Function.

Malkovskiy AV, Yacob AA, Dunn CE, Zirbes JM, Ryan SP, Bollyky PL, Rajadas J, Milla CE.

Anal Chem. 2019 Jun 18;91(12):7929-7934. doi: 10.1021/acs.analchem.9b01800. Epub 2019 Jun 4.

PMID:
31117414
2.

Filamentous bacteriophages are associated with chronic Pseudomonas lung infections and antibiotic resistance in cystic fibrosis.

Burgener EB, Sweere JM, Bach MS, Secor PR, Haddock N, Jennings LK, Marvig RL, Johansen HK, Rossi E, Cao X, Tian L, Nedelec L, Molin S, Bollyky PL, Milla CE.

Sci Transl Med. 2019 Apr 17;11(488). pii: eaau9748. doi: 10.1126/scitranslmed.aau9748.

PMID:
30996083
3.

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults.

Kim J, Farahmand M, Dunn C, Milla CE, Horii RI, Thomas EAC, Moss RB, Wine JJ.

Sci Rep. 2018 Nov 2;8(1):16233. doi: 10.1038/s41598-018-34308-8.

4.

Tear Down This Wall: Diversity and Disparities in Cystic Fibrosis.

Buu MC, Milla CE.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):983-984. doi: 10.1164/rccm.201806-1076ED. No abstract available.

PMID:
30063377
5.

Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.

Schwarz C, Hartl D, Eickmeier O, Hector A, Benden C, Durieu I, Sole A, Gartner S, Milla CE, Barry PJ.

Mycopathologia. 2018 Feb;183(1):21-32. doi: 10.1007/s11046-017-0182-0. Epub 2017 Jul 31. Review.

PMID:
28762125
6.

Lung clearance index is sensitive to small airway disease in pediatric lung transplant recipients.

Kao JE, Zirbes JM, Conrad CK, Milla CE.

J Heart Lung Transplant. 2017 Sep;36(9):980-984. doi: 10.1016/j.healun.2017.05.004. Epub 2017 May 10.

PMID:
28651906
7.

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group.

Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9. Erratum in: Lancet Respir Med. 2017 Aug;5(8):e28.

8.

Corrections to an ATS Workshop Report on Multiple-Breath Washout Testing for Patients with Cystic Fibrosis.

Subbarao P, Milla CE, Morgan WJ, Ratjen F; Workshop Authorship Group.

Ann Am Thorac Soc. 2017 Jan;14(1):145. doi: 10.1513/AnnalsATS.201610-796LE. No abstract available.

9.

Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.

Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; VX13-809-011 Part B Investigator Group *.

Am J Respir Crit Care Med. 2017 Apr 1;195(7):912-920. doi: 10.1164/rccm.201608-1754OC.

10.

Response.

Buu MC, Milla CE, Wise PH.

Chest. 2016 Sep;150(3):753. doi: 10.1016/j.chest.2016.07.008. No abstract available.

PMID:
27613985
11.

Airway epithelial homeostasis and planar cell polarity signaling depend on multiciliated cell differentiation.

Vladar EK, Nayak JV, Milla CE, Axelrod JD.

JCI Insight. 2016 Aug 18;1(13). pii: e88027.

12.

The evolving spectrum of ciliopathies and respiratory disease.

Milla CE.

Curr Opin Pediatr. 2016 Jun;28(3):339-47. doi: 10.1097/MOP.0000000000000358. Review.

13.

Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California.

Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH.

Chest. 2016 Feb;149(2):380-389. doi: 10.1378/chest.14-2189. Epub 2016 Jan 12.

14.

Inhaled ╬▓2-Agonist Therapy Increases Functional Residual Capacity in Mechanically Ventilated Children With Respiratory Failure.

Ramsi MA, Henry M, Milla CE, Cornfield DN.

Pediatr Crit Care Med. 2015 Sep;16(7):e189-93. doi: 10.1097/PCC.0000000000000448.

PMID:
25901546
15.

Recent advances in cystic fibrosis.

Milla CE, Moss RB.

Curr Opin Pediatr. 2015 Jun;27(3):317-24. doi: 10.1097/MOP.0000000000000226. Review.

PMID:
25888148
16.

Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype.

Knowles MR, Ostrowski LE, Leigh MW, Sears PR, Davis SD, Wolf WE, Hazucha MJ, Carson JL, Olivier KN, Sagel SD, Rosenfeld M, Ferkol TW, Dell SD, Milla CE, Randell SH, Yin W, Sannuti A, Metjian HM, Noone PG, Noone PJ, Olson CA, Patrone MV, Dang H, Lee HS, Hurd TW, Gee HY, Otto EA, Halbritter J, Kohl S, Kircher M, Krischer J, Bamshad MJ, Nickerson DA, Hildebrandt F, Shendure J, Zariwala MA.

Am J Respir Crit Care Med. 2014 Mar 15;189(6):707-17. doi: 10.1164/rccm.201311-2047OC.

17.

Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.

Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, Ratjen F.

Lancet Respir Med. 2013 Oct;1(8):630-638. doi: 10.1016/S2213-2600(13)70182-6. Epub 2013 Sep 10. Erratum in: Lancet Respir Med. 2017 Jul;5(7):e26.

PMID:
24461666
18.

Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia.

Austin-Tse C, Halbritter J, Zariwala MA, Gilberti RM, Gee HY, Hellman N, Pathak N, Liu Y, Panizzi JR, Patel-King RS, Tritschler D, Bower R, O'Toole E, Porath JD, Hurd TW, Chaki M, Diaz KA, Kohl S, Lovric S, Hwang DY, Braun DA, Schueler M, Airik R, Otto EA, Leigh MW, Noone PG, Carson JL, Davis SD, Pittman JE, Ferkol TW, Atkinson JJ, Olivier KN, Sagel SD, Dell SD, Rosenfeld M, Milla CE, Loges NT, Omran H, Porter ME, King SM, Knowles MR, Drummond IA, Hildebrandt F.

Am J Hum Genet. 2013 Oct 3;93(4):672-86. doi: 10.1016/j.ajhg.2013.08.015.

19.

Pricing for orphan drugs: will the market bear what society cannot?

O'Sullivan BP, Orenstein DM, Milla CE.

JAMA. 2013 Oct 2;310(13):1343-4. doi: 10.1001/jama.2013.278129. No abstract available.

PMID:
24084916
20.

Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Milla CE, Chmiel JF, Accurso FJ, VanDevanter DR, Konstan MW, Yarranton G, Geller DE; KB001 Study Group.

Pediatr Pulmonol. 2014 Jul;49(7):650-8. doi: 10.1002/ppul.22890. Epub 2013 Sep 9.

21.

Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California.

Prach L, Koepke R, Kharrazi M, Keiles S, Salinas DB, Reyes MC, Pian M, Opsimos H, Otsuka KN, Hardy KA, Milla CE, Zirbes JM, Chipps B, O'Bra S, Saeed MM, Sudhakar R, Lehto S, Nielson D, Shay GF, Seastrand M, Jhawar S, Nickerson B, Landon C, Thompson A, Nussbaum E, Chin T, Wojtczak H; California Cystic Fibrosis Newborn Screening Consortium.

J Mol Diagn. 2013 Sep;15(5):710-22. doi: 10.1016/j.jmoldx.2013.05.006. Epub 2013 Jun 28.

22.

Cystic fibrosis in the era of genomic medicine.

Milla CE.

Curr Opin Pediatr. 2013 Jun;25(3):323-8. doi: 10.1097/MOP.0b013e328360dbf5. Review.

PMID:
23652683
23.

Exome sequencing identifies mutations in CCDC114 as a cause of primary ciliary dyskinesia.

Knowles MR, Leigh MW, Ostrowski LE, Huang L, Carson JL, Hazucha MJ, Yin W, Berg JS, Davis SD, Dell SD, Ferkol TW, Rosenfeld M, Sagel SD, Milla CE, Olivier KN, Turner EH, Lewis AP, Bamshad MJ, Nickerson DA, Shendure J, Zariwala MA; Genetic Disorders of Mucociliary Clearance Consortium.

Am J Hum Genet. 2013 Jan 10;92(1):99-106. doi: 10.1016/j.ajhg.2012.11.003. Epub 2012 Dec 20.

24.

Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis.

Blainey PC, Milla CE, Cornfield DN, Quake SR.

Sci Transl Med. 2012 Sep 26;4(153):153ra130.

25.

Effect of endoscopic sinus surgery on pulmonary status of adults with cystic fibrosis.

Kempainen RR, Sajan JA, Pylkas AM, Dunitz JM, Rimell FL, Milla CE.

Otolaryngol Head Neck Surg. 2012 Sep;147(3):557-62. doi: 10.1177/0194599812444247. Epub 2012 Apr 18.

PMID:
22517014
26.

Pulmonary complications of endocrine and metabolic disorders.

Milla CE, Zirbes J.

Paediatr Respir Rev. 2012 Mar;13(1):23-8. doi: 10.1016/j.prrv.2011.01.004. Epub 2011 Feb 22. Review.

PMID:
22208790
27.

Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: a multicenter experience.

Olin JT, Burns K, Carson JL, Metjian H, Atkinson JJ, Davis SD, Dell SD, Ferkol TW, Milla CE, Olivier KN, Rosenfeld M, Baker B, Leigh MW, Knowles MR, Sagel SD; Genetic Disorders of Mucociliary Clearance Consortium.

Pediatr Pulmonol. 2011 May;46(5):483-8. doi: 10.1002/ppul.21402. Epub 2011 Jan 31.

28.

Characteristics of gastroesophageal reflux in adults with cystic fibrosis.

Sabati AA, Kempainen RR, Milla CE, Ireland M, Schwarzenberg SJ, Dunitz JM, Khan KM.

J Cyst Fibros. 2010 Sep;9(5):365-70. doi: 10.1016/j.jcf.2010.06.004. Epub 2010 Jul 31.

29.

Nutrition in cystic fibrosis.

Matel JL, Milla CE.

Semin Respir Crit Care Med. 2009 Oct;30(5):579-86. doi: 10.1055/s-0029-1238916. Epub 2009 Sep 16. Review.

PMID:
19760545
30.

Cystic fibrosis related diabetes.

Zirbes J, Milla CE.

Paediatr Respir Rev. 2009 Sep;10(3):118-23; quiz 123. doi: 10.1016/j.prrv.2009.04.004. Epub 2009 Jul 14. Review.

PMID:
19651382
31.

Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis.

Harrison AN, Regelmann WE, Zirbes JM, Milla CE.

Pediatr Pulmonol. 2009 Apr;44(4):330-9. doi: 10.1002/ppul.20994.

PMID:
19274621
32.

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis.

Zirbes JM, Milla CE.

Pediatr Pulmonol. 2008 Jun;43(6):607-10. doi: 10.1002/ppul.20804.

PMID:
18433040
33.

Comparison of high-frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis.

Kempainen RR, Williams CB, Hazelwood A, Rubin BK, Milla CE.

Chest. 2007 Oct;132(4):1227-32. Epub 2007 Sep 21.

PMID:
17890465
34.

Nutrition and lung disease in cystic fibrosis.

Milla CE.

Clin Chest Med. 2007 Jun;28(2):319-30. Review.

PMID:
17467551
35.

Different frequencies should be prescribed for different high frequency chest compression machines.

Milla CE, Hansen LG, Warwick WJ.

Biomed Instrum Technol. 2006 Jul-Aug;40(4):319-24.

PMID:
16941931
36.

Inflammatory cytokines and the development of pulmonary complications after allogeneic hematopoietic cell transplantation in patients with inherited metabolic storage disorders.

Kharbanda S, Panoskaltsis-Mortari A, Haddad IY, Blazar BR, Orchard PJ, Cornfield DN, Grewal SS, Peters C, Regelmann WE, Milla CE, Baker KS.

Biol Blood Marrow Transplant. 2006 Apr;12(4):430-7.

37.

Cystic fibrosis pulmonary exacerbations.

Ferkol T, Rosenfeld M, Milla CE.

J Pediatr. 2006 Feb;148(2):259-64. Review. No abstract available.

PMID:
16492439
38.
39.

Natural history of pulmonary complications in children after bone marrow transplantation.

Eikenberry M, Bartakova H, Defor T, Haddad IY, Ramsay NK, Blazar BR, Milla CE, Cornfield DN.

Biol Blood Marrow Transplant. 2005 Jan;11(1):56-64.

40.

Association of nutritional status and pulmonary function in children with cystic fibrosis.

Milla CE.

Curr Opin Pulm Med. 2004 Nov;10(6):505-9. Review.

PMID:
15510058
41.

Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis.

Garner HP, Phillips JR, Herron JG, Severson SJ, Milla CE, Regelmann WE.

J Lab Clin Med. 2004 Sep;144(3):127-33.

PMID:
15454881
42.

High-frequency chest compression: effect of the third generation compression waveform.

Milla CE, Hansen LG, Weber A, Warwick WJ.

Biomed Instrum Technol. 2004 Jul-Aug;38(4):322-8.

PMID:
15338841
43.
44.

Safety of inhaled nitric oxide after lung transplantation.

Cornfield DN, Milla CE, Haddad IY, Barbato JE, Park SJ.

J Heart Lung Transplant. 2003 Aug;22(8):903-7.

PMID:
12909471
45.

Continuous propofol infusion in 142 critically ill children.

Cornfield DN, Tegtmeyer K, Nelson MD, Milla CE, Sweeney M.

Pediatrics. 2002 Dec;110(6):1177-81.

PMID:
12456916
46.

Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline.

Milla CE, Warwick WJ, Moran A.

Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):891-5.

PMID:
10988101
47.

Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension.

Cornfield DN, Maynard RC, deRegnier RA, Guiang SF 3rd, Barbato JE, Milla CE.

Pediatrics. 1999 Nov;104(5 Pt 1):1089-94.

PMID:
10545552
48.

Recombinant human DNase in cystic fibrosis.

Milla CE.

Lancet. 1999 Jul 31;354(9176):428. No abstract available.

PMID:
10437902
49.

NO causes perinatal pulmonary vasodilation through K+-channel activation and intracellular Ca2+ release.

Saqueton CB, Miller RB, Porter VA, Milla CE, Cornfield DN.

Am J Physiol. 1999 Jun;276(6):L925-32. doi: 10.1152/ajplung.1999.276.6.L925.

PMID:
10362716
50.

High levels of peroxynitrite are generated in the lungs of irradiated mice given cyclophosphamide and allogeneic T cells. A potential mechanism of injury after marrow transplantation.

Haddad IY, Panoskaltsis-Mortari A, Ingbar DH, Yang S, Milla CE, Blazar BR.

Am J Respir Cell Mol Biol. 1999 Jun;20(6):1125-35.

PMID:
10340931

Supplemental Content

Loading ...
Support Center